Author: A. Ant, CADC-II, Licensing & Accreditation Expert
California MAT Requirements: The BHIN 23-054 Access Expectation for SUD Programs
Most operators assume medication-assisted treatment in California is a licensing question that belongs to methadone clinics. For nearly every DHCS-licensed or certified SUD program, the requirement that actually matters is a different one entirely.
The part that catches people off guard
Here’s what’s easy to miss: under DHCS’s current guidance (BHIN 23-054), MAT access isn’t limited to programs that hold an NTP license anymore. Any DHCS-licensed or certified SUD program (residential or outpatient, not just narcotic treatment programs) is now expected to offer or facilitate access to FDA-approved medications for substance use disorder. That covers opioid use disorder medications, but it isn’t limited to opioids; it applies to FDA-approved medications for alcohol use disorder too, and to whatever else the FDA approves going forward. A residential program that has never touched methadone can still be out of compliance here if it has no pathway (direct or facilitated through referral) to get a resident access to buprenorphine or naltrexone when clinically indicated.
“Facilitating access” doesn’t mean every facility has to dispense on-site. It means having a real, working relationship with a prescriber or an NTP that can get a patient started without weeks of delay. DHCS’s expectation is that MAT starts as soon as clinically appropriate, particularly when withdrawal symptoms are present, not whenever a referral eventually goes through.
Dedicated narcotic treatment licensure is a separate track
Operating a Narcotic Treatment Program under Title 9, CCR, Division 4, Chapter 4 is its own licensing path, and this article doesn’t cover it. A program that isn’t an NTP still owes the access pathway described above.
Frequently Asked Questions
Does BHIN 23-054 only apply to programs that hold a Narcotic Treatment Program license?
No. It applies to any DHCS-licensed or certified SUD program, residential or outpatient, whether or not it holds an NTP license. The access expectation is separate from NTP-specific licensure under Title 9.
Does a residential program have to dispense MAT medications on-site to comply?
No. DHCS’s expectation is a real, working pathway, direct or through a referral relationship with a prescriber or NTP, that gets a patient started without weeks of delay, not on-site dispensing itself.
Is BHIN 23-054 limited to opioid use disorder medications?
No. It covers FDA-approved medications for alcohol use disorder as well, and extends to whatever else the FDA approves going forward, not just opioid-specific medications.
See the California Behavioral Health Licensing page for the broader regulatory picture.
This content is provided for general informational purposes only and should not be construed as medical, clinical, legal, financial, tax, accounting, insurance, licensing, accreditation, regulatory, billing, employment, or compliance advice. Requirements change often. Consult qualified professionals for guidance specific to your situation.
Building a BHIN 23-054 access pathway for a California SUD program? Let’s talk it through.
Leave a Reply